Financing - August 10, 2022
Zealand Pharma announces voluntary delisting from Nasdaq Global Select Market
Zealand Pharma has given formal notice to Nasdaq of the company’s intention to voluntarily remove its American Depositary Shares (ADSs) from listing on the New York-based Nasdaq Global Select Market. One ADS currently represents one ordinary share in Zealand Pharma, and today the company’s ADSs account for less than 1.5% of the total share capital. […]
Financing - August 4, 2022
Iconovo receives grant from the Bill & Melinda Gates Foundation
Iconovo has received a grant of USD 883,800 from the Bill & Melinda Gates Foundation. The grant work plan is focused on the development of a low-cost device that can provide delivery of medical compounds to the full (upper and lower) respiratory tract and will be performed in the period August 2022 – June 2023. […]
Financing - July 14, 2022
Trading in SynAct Pharma’s shares has commenced
SynAct Pharma has announced that its share started trading on Nasdaq Stockholm’s main list July 12, 2022. “SynAct Pharma has worked hard with its pipeline to make it to where it is today. To be traded on the main market is an important landmark and a stamp of quality for SynAct, which enables us to […]
Biotech Business - July 13, 2022
BioInvent raises 300 million SEK
The Board of Directors of BioInvent International has resolved to issue 6,496,788 new shares in a directed share issue to international and Swedish institutional investors based on the authorization granted by the Annual General Meeting on April 28, 2022. “The performed directed share issue provides us with an even stronger base of institutional investors and […]
Financing - June 22, 2022
OnDosis completes a private placement of 75 million SEK
Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen. The private placement enables acceleration of new projects in collaboration with an unnamed license partner as well as the building of the digital platform for the company to develop and introduce closed loop disease […]
Biotech Business - June 20, 2022
Elypta raises 21 million USD
Elypta has announced the raise of 21 million USD in a series A financing round led by Bonnier Ventures. “The series A is a pivotal moment for Elypta as it fully funds the development of our two leading indications,” says Karl Bergman, CEO at Elypta. “We believe it has great potential to improve cancer outcomes” […]
